EN DE
STOCK COMPARISON

Yifan Xinfu Pharmaceutical Co vs Eli Lilly and: Fair Value & Quality

Both stocks run through our valuation models. Here is how Yifan Xinfu Pharmaceutical Co (002019) and Eli Lilly and (LLY) compare, as of Sep 24, 2026.

As of Sep 24, 2026, Fair Value Calculator sees Yifan Xinfu Pharmaceutical Co as the less overvalued of the two: Yifan Xinfu Pharmaceutical Co trades at ¥9.59 versus a fair value of ¥6.89 (-28%), while Eli Lilly and trades at $1,151 versus $791 (-31%).
Yifan Xinfu Pharmaceutical Co
002019.SHE · CNY · Health Care
-28%
upside to fair value
overvalued
Price¥9.59
Fair Value¥6.89
Quality56/100
Eli Lilly and
LLY · USD · Health Care
-31%
upside to fair value
overvalued
Price$1,151
Fair Value$791
Quality69/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

Yifan Xinfu Pharmaceutical CoEli Lilly and
Valuation
33.1×P/E (TTM)40.9×
2.31×P/S (TTM)14.31×
1.32×P/B38.95×
15.8×EV/EBITDA29.5×
0.35×PEG1.54×
−28.2%Fair value upside−31.2%
1.0%Dividend yield0.5%
¥0.10Dividend per share$6.23
Profitability
12%Operating margin49%
0.56×EBIT margin trend (5Y)1.42×
4%Return on equity107%
2%Return on assets21%
Growth
-5%Revenue growth (YoY)56%
10.2%Avg. growth/yr (3Y)31.7%
-1.0%Avg. growth/yr (5Y)21.6%
−13.9%Value creation/yr+26.5%
Balance & size
10.9×Interest coverage (EBIT/interest)37.3×
0.10×Debt / equity1.54×
$2BMarket cap$1.0T
weakGrowth qualitymixed

Even match: 8 to 8 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Yifan Xinfu Pharmaceutical Coof which business quality 54 · market factors 30 Eli Lilly andof which business quality 65 · market factors 78
ProfitabilityMargins and returns on capital today
31
85
Quality GrowthAre margins and returns improving?
54
86
CashflowEarnings quality: real cash, not paper profit
23
51
Fin. StrengthBalance sheet, leverage, solvency risk
70
53
InvestmentDisciplined investing over empire-building
82
15
Low VolatilityCalm price path (market factor)
75
77
MomentumPrice trend over the last 3–12 months (market factor)
16
75
52W MomentumDistance to the 52-week high (market factor)
3
85
Net IssuanceShare count: buybacks or dilution?
85
93

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyYifan Xinfu Pharmaceutical CoPrice ¥9.59Eli Lilly andPrice $1,151
DCF Models-62%below the price¥3.63-70%below the price$345
Earnings-Based-54%below the price¥4.44-79%below the price$239
Dividend Discountn/a-90%below the price$115
Multiples-30%below the price¥6.67-69%below the price$358
Asset-Based-49%below the price¥4.87-98%below the price$19.94
Growth DCFn/a-83%below the price$197
Economic Profit-54%below the price¥4.39-70%below the price$347
Growth Earnings-28%below the price¥6.89-67%below the price$375
Minimum-62%below the price¥3.63-98%below the price$19.94
Maximum-28%below the price¥6.89-67%below the price$375
Median-51%below the price¥4.66-75%below the price$292
Geometric mean-48%below the price¥5.01-83%below the price$190

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Yifan Xinfu Pharmaceutical Co: 13 of 15 models see the stock below the current price.

Eli Lilly and: 26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Yifan Xinfu Pharmaceutical Co
Price ¥9.59
Fair Value ¥6.89
Bear ¥4.96Bull ¥8.95
Eli Lilly and
Price $1,151
Fair Value $791
Bear $401Bull $1,165

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Yifan Xinfu Pharmaceutical Co · Health Care

Quality score56 · above median
Fair value upside-28% · below median

Eli Lilly and · Health Care

Quality score69 · Top 25%
Fair value upside-31% · below median

Bottom line

As of Sep 24, 2026, Fair Value Calculator sees Yifan Xinfu Pharmaceutical Co as the less overvalued of the two: Yifan Xinfu Pharmaceutical Co trades at ¥9.59 versus a fair value of ¥6.89 (-28%), while Eli Lilly and trades at $1,151 versus $791 (-31%).

Eli Lilly and has the higher quality score (69/100).

Open Yifan Xinfu Pharmaceutical Co live analysis →
Yifan Xinfu Pharmaceutical Co · Eli Lilly and

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Yifan Xinfu Pharmaceutical Co

Microsoft vs NvidiaApple vs MicrosoftNvidia vs Taiwan Semiconductor ManufacturingApple vs Taiwan Semiconductor Manufacturing

Related to Eli Lilly and

Alphabet Inc Class C vs Meta PlatformsCisco Systems vs NvidiaMicrosoft vs Taiwan Semiconductor ManufacturingApple vs Cisco Systems
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.